New potassium binders for the treatment of hyperkalemia: Current data and opportunities for the future

Hypertension

Volumn 66, Issue 4, 2015, Pages 731-738

  Pitt, Bertram ^a   Bakris, George L ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PATIROMER; SODIUM ZIRCONIUM CYCLOSILICATE; POTASSIUM; SILICATE; ZS-9 COMPOUND;

ACUTE DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIETARY INTAKE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PATIENT SELECTION; POTASSIUM INTAKE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; BLOOD; TREATMENT OUTCOME;

HUMANS; HYPERKALEMIA; POTASSIUM; SILICATES; TREATMENT OUTCOME;

EID: 84941206302     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.04889     Document Type: Review

References (38)

1. Palmer BF, Managing hyperkalemia caused by inhibitors of the renin-Angiotensin-Aldosterone system. N Engl J Med 2004 351 585 592. doi: 10.1056/NEJMra035279
2. Palmer BF, A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis 2010 56 387 393. doi: 10.1053/j.ajkd.2010.01.020
3. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC, The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009 169 1156 1162. doi: 10.1001/archinternmed.2009.132
4. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney inter, Suppl 2013 3 1 150
5. James PA, Oparil S, Carter BL, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 311 507 520. doi: 10.1001/jama.2013.284427
6. McMurray JJ, Adamopoulos S, Anker SD, ESC Committee for Practice Guidelines ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012 33 1787 1847. doi: 10.1093/eurheartj/ehs104
7. Yancy CW, Jessup M, Bozkurt B, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013 62 e147 e239. doi: 10.1016/j.jacc.2013.05.019
8. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS, The effect of combination treatment with aliskiren and blockers of the renin-Angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-Analysis. BMJ 2012 344 e42
9. Khosla N, Kalaitzidis R, Bakris GL, Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009 30 418 424. doi: 10.1159/000237742
10. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA, African American Study of Hypertension and Kidney Disease Collaborative Research Group Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009 169 1587 1594. doi: 10.1001/archinternmed.2009.284
11. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012 367 2204 2213. doi: 10.1056/NEJMoa1208799
12. Mancia G, Fagard R, Narkiewicz K, Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013 31 1281 1357. doi: 10.1097/01.hjh.0000431740.32696.cc
13. American Diabetes Association Cardiovascular disease and risk management. Diabetes Care 2015 38 S49 S57
14. National Kidney Foundation K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 43 S1 S290
15. Sterns RH, Rojas M, Bernstein P, Chennupati S, Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010 21 733 735. doi: 10.1681/ASN.2010010079
16. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B, Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015 372 222 231. doi: 10.1056/NEJMoa1411487
17. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015 372 211 221. doi: 10.1056/NEJMoa1410853
18. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, PEARL-HF Investigators Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011 32 820 828. doi: 10.1093/eurheartj/ehq502
19. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA 2015 314 151 161. doi: 10.1001/jama.2015.7446
20. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B, Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014 312 2223 2233. doi: 10.1001/jama.2014.15688
21. Weir MR, Rolfe M, Potassium homeostasis and renin-Angiotensin-Aldosterone system inhibitors. Clin J Am Soc Nephrol 2010 5 531 548. doi: 10.2215/CJN.07821109
22. Lazich I, Bakris GL, Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014 34 333 339. doi: 10.1016/j.semnephrol.2014.04.008
23. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004 351 543 551. doi: 10.1056/NEJMoa040135
24. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S, Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012 109 1510 1513. doi: 10.1016/j.amjcard.2012.01.367
25. Collins A, Reaven N, Funk S, McGaughey K, Bakris G, Pitt B, Bushinsky D, Potassium levels and mortality in patients with CKD [abstract]. J Am Soc Neprhol 2014. Abstract No. TH-P0705
26. Pitt B, Collins A, Reaven N, Funk S, Bakris G, Bushinsky D, Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium [abstract]. Circulation 2014 130 A13320
27. Houghton AR, Cowley AJ, Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997 59 7 10
28. Tamargo J, Caballero R, Delpón E, New drugs for the treatment of hyperkalemia in patients treated with renin-Angiotensin-Aldosterone system inhibitors-hype or hope? Discov Med 2014 18 249 254
29. McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow GC, Goyal A, Herzog CA, Kosiborod M, Palmer BF, Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Rev Cardiovasc Med 2014 15 11 23
30. Buysse JM, Huang IZ, Pitt B, PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012 8 17 28. doi: 10.2217/fca.11.71
31. Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS, Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One 2014 9 e114686. doi: 10.1371/journal.pone.0114686
32. Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR, Management of patients with acute hyperkalemia. CMAJ 2010 182 1631 1635. doi: 10.1503/cmaj.100461
33. Weisberg LS, Management of severe hyperkalemia. Crit Care Med 2008 36 3246 3251. doi: 10.1097/CCM.0b013e31818f222b
34. Montague BT, Ouellette JR, Buller GK, Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol 2008 3 324 330. doi: 10.2215/CJN.04611007
35. Szerlip HM, Weiss J, Singer I, Profound hyperkalemia without electrocardiographic manifestations. Am J Kidney Dis 1986 7 461 465
36. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM, Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev 2005 CD003235
37. Kosiborod M, Peacock WF, Packham DK, Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. N Engl J Med 2015 372 1577 1578. doi: 10.1056/NEJMc1500353
38. Bushinsky DA, Bakris GL, Williams G, Pitt B, Mayo M, Garza D, Stasiv Y, Li E, Berman L, Patiromer induced a rapid onset of action and sustained K+ lowering throughout the dosing period in CKD patients with hyperkalemia [abstract SA-PO153]. J Am Soc Nephrol 2014 25 669A